Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,360 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07243834Recruiting
Digital exercise program for prostate cancer patients on hormone therapy
This trial tests a digital exercise program to see if it helps men with prostate cancer stay active while on hormone therapy. You may be able to join if you're starting or already on hormone therapy and also getting radiation therapy.
LondonAges 18 years+ - NCT07249281Recruiting
New MRI scan for better prostate cancer detection
This study tests a new type of MRI scan (called TDDMRI) that looks at tiny details in prostate tissue to better detect cancer. If you are already getting a prostate MRI, this extra scan may help doctors find cancer more accurately.
Beijing, Beijing MunicipalityAges Any age - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT07245745Recruiting
Comparing two types of radiotherapy for prostate cancer
This trial compares adaptive radiotherapy (which adjusts to changes in your body) with conventional radiotherapy for prostate cancer. It aims to see which approach leads to better patient-reported outcomes.
BrusselsAges 18 years+ - NCT07242014Recruiting
New PET scan for prostate cancer
This trial tests a new PET scan called XACP3 to see if it can find prostate cancer as well as the standard PSMA PET scan. You could help by having both scans to compare them.
Xiamen, FujianAges 18–80 - NCT06482489Recruiting
Low-field MRI for better prostate imaging
This study tests a new, lower-strength MRI to see if it can give clearer images of the prostate, especially for men who have metal implants or who need a biopsy. It may help doctors monitor prostate health more safely and effectively.
Lausanne, Canton of VaudAges 18 years+ - NCT07234981RecruitingPhase 2
Using PSMA-PET to guide less intense radiation for returning prostate cancer
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
Omaha, NebraskaAges 30 years+ - NCT07237269RecruitingPhase 2
Abiraterone/prednisone plus ADT for early prostate cancer
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
Omaha, NebraskaAges 30 years+ - NCT07231159Recruiting
Cancer screening help at community spots
This trial tests a program to help people get screened for lung, breast, or prostate cancer at community resource spots. If you are at risk and screen positive, you may be able to join.
Orlando, FloridaAges 18 years+ - NCT07224009RecruitingPhase 2
Low dose naltrexone for fatigue in prostate cancer on hormone therapy
This trial tests if a low dose of the drug naltrexone can help reduce fatigue in men with prostate cancer who are currently receiving hormone therapy (ADT). It may offer a new way to manage tiredness during treatment.
Little Rock, ArkansasAges 18 years+ - NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT07222436Recruiting
Blood test for high-risk prostate cancer
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07230106RecruitingPhase 2
Study of 3 drugs for men with prostate cancer
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Nanjing, JiangsuAges 18–80 - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Chandler, ArizonaAges 18 years+ - NCT07223372Recruiting
Study on male hormone blocking drugs for prostate cancer in Australia
This study looks at how certain drugs (darolutamide, enzalutamide, apalutamide, or abiraterone) that block male hormones are used to treat men with prostate cancer that has spread. It aims to understand real-world treatment patterns in Australia.
Pymble, New South WalesAges 18 years+ - NCT07214675Recruiting
Sound wave treatment for enlarged prostate
This trial tests a new treatment that uses focused sound waves to break down extra prostate tissue without cutting or heat. It may help men with an enlarged prostate who have bothersome urinary symptoms.
ShatinAges 50 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Goodyear, ArizonaAges 18 years+ - NCT07216248RecruitingPhase 2
Smart monitoring for men with advanced prostate cancer
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Salt Lake City, UtahAges 18 years+ - NCT07218666RecruitingPhase 2
Zanzalintinib for aggressive prostate cancer
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Milwaukee, WisconsinAges 18 years+ - NCT07219303Recruiting
Adaptive radiation therapy for intermediate- or high-risk prostate cancer
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06480110RecruitingPhase 1/Phase 2
Ebastine plus docetaxel for advanced prostate cancer
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
CopenhagenAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT07205783Enrolling by invitation
Comparing surgery and radiation for early prostate cancer
This trial compares two standard treatments for prostate cancer that hasn't spread: surgery to remove the prostate (radical prostatectomy) and radiation therapy (curative radiotherapy). It looks back at past patients to see which treatment worked better.
SohagAges 40 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,360 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.